The global vaccine contract manufacturing market was valued at USD 3.0 Billion in 2024 and is projected to reach USD 6.3 Billion by 2033, growing at a CAGR of 8.45% during the forecast period of 2025-2033. Market growth is driven by expanding vaccine demand, advancements in biologic vaccine technology like mRNA and viral vectors, and the necessity for flexible, scalable production capacity, all facilitated by contract manufacturing organizations (CMOs). Increased government immunization initiatives and rising infectious disease prevalence also boost outsourcing to CMOs in the vaccine production sector. 

The global Vaccine Contract Manufacturing Market Size is expanding rapidly as pharmaceutical companies increasingly outsource production to meet rising vaccine demand and ensure faster scalability. Key drivers include growing immunization programs, advancements in biotechnology, and the need for specialized manufacturing capabilities. The shift toward mRNA, viral vector, and recombinant vaccines is also boosting the Vaccine Contract Manufacturing Market Size, as CDMOs offer expertise, cost-efficiency, and regulatory compliance. Additionally, pandemic preparedness initiatives and increased investment in bioprocessing infrastructure are supporting strong market growth worldwide.

Study Assumption Years

• **Base Year:** 2024
• **Historical Year/Period:** 2019-2024
• **Forecast Year/Period:** 2025-2033

Vaccine Contract Manufacturing Market Key Takeaways

• The market size was USD 3.0 Billion in 2024.
• The market CAGR is 8.45% from 2025-2033.
• The forecast period covers 2025 to 2033.
• North America leads with a 36% market share in 2024.
• The expansion of CMOs and government support via grants and subsidies are key market propellers.
• The rising pipeline of advanced vaccines, including mRNA and viral vector platforms, underscores specialized technology needs.
• High vaccine R&D and production costs are driving outsourcing to contract manufacturers.

Request a Sample Report: https://www.imarcgroup.com/vaccine-contract-manufacturing-market/requestsample

Market Growth Factors

The global vaccine contract manufacturing market is expanding due to rising demand driven by increasing infectious disease prevalence, a greater emphasis on preventive healthcare, and preparations for possible future pandemics. Governments worldwide prioritize immunization strategies by offering grants, subsidies, and procurement commitments that reduce financial risks and encourage outsourcing to specialized CMOs with advanced infrastructure and regulatory expertise. This widespread government backing not only fosters innovation and global vaccine access but also accelerates regulatory approvals during emergencies, enhancing confidence in contract manufacturing.

High research and production costs deter many pharmaceutical and biotech companies from building large-scale manufacturing facilities. Consequently, these companies prefer outsourcing processes to CMOs, which offer cost-effective solutions and regulatory compliance expertise. The expanding pipeline for advanced vaccines, especially those based on messenger ribonucleic acid (mRNA) and viral vector platforms, demands specialized technologies and flexible manufacturing capacities that CMOs provide efficiently. Furthermore, advances in bioprocessing technologies complement the necessity for scalable, adaptable production to meet market needs while reducing time-to-market pressures.

The increasing awareness about vaccination among individuals, communities, and governments positively influences this market. Vaccination programs are progressively expanding due to vaccines’ role in preventing infectious diseases and reducing healthcare burdens. Vaccines also help reduce antibiotic use and associated ailments. According to WHO, vaccination prevents 3.5 to 5 million deaths annually from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. This rising consciousness encourages pharmaceutical firms to rapidly scale vaccine production through outsourcing to CMOs, who provide the required expertise, infrastructure, and capacity for quality and compliant manufacturing.

Market Segmentation

By Vaccine Type:

• Attenuated
• Inactivated: Holds 33.4% of the market share in 2024. These vaccines contain killed or non-replicating pathogens, making them suitable for immunocompromised individuals and mass immunization campaigns. Their production is standardized and regulated, facilitating easier scale-up by contract manufacturers and widespread use against diseases like influenza, polio, hepatitis A, and rabies.
• Subunit-based
• Toxoid-based
• DNA-based

By Workflow:

• Downstream: Fill and Finish Operations, Analytical and QC Studies, Packaging
• Account for 58% of the market share. Downstream processes ensure vaccine purity, safety, and efficacy before distribution, involving complex, resource-intensive steps like purification and formulation. This stage improves yield, batch consistency, and contamination control, especially crucial for sophisticated vaccines like mRNA and viral vector types.
• Upstream: Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Others

By Application:

• Human Use: Holds 85% of the market share. Human vaccines are critical for preventing infectious diseases, reducing morbidity and mortality, and supporting public health, driving large-scale immunization investments globally. Pharmaceutical and biotech companies often outsource manufacturing to CMOs equipped to meet stringent regulatory and production standards.
• Veterinary

Regional Insights

North America leads with a 36% market share in 2024, supported by a robust biotechnology and pharmaceutical ecosystem, advanced infrastructure, strong R&D investments, and the presence of leading contract manufacturing organizations. Strict regulatory frameworks and substantial government funding for immunization programs further strengthen this region's leadership, consolidating its dominance in vaccine innovation, manufacturing, and outsourcing.

Recent Developments & News

• June 2025: Boehringer Ingelheim launched a new single-dose vaccine for poultry in India, targeting diseases such as Bursal, Newcastle, and Marek’s, enhancing immunity, reducing labor, stress, and promoting antibiotic reduction in agriculture.
• May 2025: TPG acquired a 35% stake in SCHOTT Poonawalla from Serum Institute of India; SCHOTT Pharma retains 50%. This partnership aims to strengthen global presence and innovation in injectables and vaccine contract production.
• May 2025: Sanofi and Vietnam Vaccine Company initiated a USD 77.2 Million collaboration for local vaccine production in Vietnam, including technology transfer and training, targeting 100 million doses annually.
• January 2025: GeoVax enhanced its MVA vaccine production using an avian suspension cell line, improving yield, cost efficiency, and scalability, helping global vaccine accessibility including its COVID-19 candidate.
• December 2024: Bavarian Nordic partnered with Serum Institute of India for Mpox vaccine manufacturing, improving epidemic readiness through technology sharing and contract production.

Key Players

• Ajinomoto Co. Inc.
• Albany Molecular Research Inc
• Catalent Inc
• Cobra Biologics Limited (Charles River Laboratories International Inc.)
• Cytovance Biologics Inc. (Hepalink USA Inc.)
• Fujifilm Holdings Corporation
• ICON plc
• IDT Biologika GmbH
• Lonza Group AG
• Merck KGaA
• Pharmaceutical Product Development LLC
• PRA Health Sciences Inc.

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=3872&flag=C

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302